NDA 022083 · Sandoz
Exelon
Rivastigmine · Transdermal · Cholinesterase Inhibitor
Last checked: Nov 20, 2026Latest source record: May 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Jul 6, 2007
Approved uses
3
Original approval plus efficacy supplements
Registered trials
100
26 Phase 3, 4 recruiting
FAERS reports
18,807
16,024 serious, 4,787 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 8, 2024.
EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: • Mild, moderate, and severe dementia of the Alzheimer’s type (AD). ( 1.1 ) • Mild-to-moderate dementia associated with Parkinson’s disease (PD). ( 1.2 ) 1.1 Alzheimer’s Disease EXELON PATCH is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. 1.2 Parkinson’s Disease Dementia EXELON PATCH is indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PDD).
Mechanism: Although the precise mechanism of action of rivastigmine is unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that rivastigmine alters the course of the underlying dementing process.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 27, 2013 Supplement 19 · Efficacy LabelLetter
- Aug 31, 2012 Supplement 16 · Efficacy ReviewLetterLabel
- Jul 6, 2007 Original approval · Type 3 - New Dosage Form ReviewLabel
3 products under this application
- EXELON · RIVASTIGMINE 9.5MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- EXELON · RIVASTIGMINE 13.3MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- EXELON · RIVASTIGMINE 4.6MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rivastigmine" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive DeclinePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00506415 · 1,584 participants · Start Jun 2007 · Primary completion May 2011
Drug: Rivastigmine 5 cm^2; Rivastigmine 10 cm^2 and 3 more · For: Alzheimer Disease
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 145 sites in all
- Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)Pivotal-lookingNot yet recruiting
University Hospital, BordeauxAcademic, hospital or other
NCT03454646 · 1,205 participants (planned) · Start Jun 1, 2024 · Primary completion Apr 27, 2027
Drug: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) · For: Alzheimer Disease; Cholinesterase Inhibitors
Sites: Amiens, France; Angers, France; Bastia, France · 31 sites in all
- Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseasePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00099242 · 1,040 participants · Start Nov 2003
Drug: rivastigmine transdermal patch · For: Alzheimer's Disease; Dementia, Alzheimer Type
Sites: Orange, California; San Francisco, California; Boca Raton, Florida · 75 sites in all
- An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseasePivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00219232 · 868 participants · Start Feb 2003 · Primary completion Jul 2006
Drug: Rivastigmine Transdermal Patch · For: Alzheimer's Disease
- Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's DiseasePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00423085 · 859 participants · Start Jan 2007 · Primary completion Mar 2009
Drug: Rivastigmine transdermal patch; Placebo · For: Alzheimer's Disease
Sites: Hokkaido Region, Japan
- Masitinib in Patients With Mild to Moderate Alzheimer's DiseasePivotal-lookingCompleted
AB ScienceIndustry
NCT01872598 · 721 participants · Start Jan 2012 · Primary completion Dec 2020
Drug: Masitinib; Placebo and 1 more · For: Alzheimer Disease
Sites: Varna, Bulgaria; Thessaloniki, Greece; Bialystok, Poland · 6 sites in all
NovartisNovartis (NVS)
NCT00948766 · 716 participants · Start Jul 2009 · Primary completion Jan 2012
Drug: Rivastigmine 4.6 mg/24 h (5 cm^2); Rivastigmine 9.5 mg/24 h (10 cm^2) and 2 more · For: Alzheimer's Disease
Sites: Tempe, Arizona; Tucson, Arizona; Conway, Arkansas · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death2,337
- fall1,791
- hallucination1,475
- confusional state1,331
- drug ineffective957
- vomiting909
- nausea858
- dizziness811
- gait disturbance751
- pneumonia728
- somnolence692
- fatigue681
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 323 |
| 2005 | 236 |
| 2006 | 201 |
| 2007 | 226 |
| 2008 | 611 |
| 2009 | 904 |
| 2010 | 943 |
| 2011 | 1,364 |
| 2012 | 1,451 |
| 2013 | 411 |
| 2014 | 611 |
| 2015 | 673 |
| 2016 | 941 |
| 2017 | 944 |
| 2018 | 984 |
| 2019 | 841 |
| 2020 | 1,048 |
| 2021 | 906 |
| 2022 | 936 |
| 2023 | 952 |
| 2024 | 1,009 |
| 2025 | 1,310 |
| 2026 | 977 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Exelon (Rivastigmine)
2024 spending
$10.4M
Beneficiaries
2,813
12,602 claims
Per beneficiary
$3,710
$22.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $58,031,637 |
| 2021 | $37,741,853 |
| 2022 | $25,954,523 |
| 2023 | $19,709,214 |
| 2024 | $10,434,913 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dementia.
Butler R, Radhakrishnan R · BMJ Clin Evid 2012 · Systematic Review
- Dementia.
Warner JP, Butler R, Gupta S · BMJ Clin Evid 2010 · Systematic Review
- Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review.
Chen Y, Lai M, Tao M · Medicine (Baltimore) 2024 · Meta-Analysis, Systematic Review
- Cholinesterase inhibitors for Alzheimer's disease.
Birks J · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review.
Blackman J, Swirski M, Clynes J, et al. · J Sleep Res 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.